Tübingen, Germany

Bent Pfaffenrot

This inventor holds 1 USPTO granted patent. Top assignee: Heparegenix Gmbh. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bent Pfaffenrot: Innovator in Liver Regeneration

Introduction

Bent Pfaffenrot is a notable inventor based in Tübingen, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that promote liver regeneration. His work is crucial for advancing treatments for liver-related diseases.

Latest Patents

Pfaffenrot holds a patent for "Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death." This invention focuses on pyrazolo-pyridine compounds that inhibit mitogen-activated protein kinase kinase 4 (MKK4). These compounds selectively inhibit MKK4 over protein kinases JNK1 and MKK7. They are beneficial for promoting liver regeneration and reducing hepatocyte death. Additionally, they have potential applications in treating osteoarthritis, rheumatoid arthritis, and CNS-related diseases. He has 1 patent to his name.

Career Highlights

Pfaffenrot is associated with Heparegenix GmbH, a company dedicated to innovative solutions in liver health. His work at the company emphasizes the importance of research in developing effective treatments for liver conditions.

Collaborations

He collaborates with notable colleagues such as Wolfgang Albrecht and Stefan Laufer. Their combined expertise contributes to the advancement of research in their field.

Conclusion

Bent Pfaffenrot is a key figure in the development of innovative treatments for liver regeneration. His contributions through patents and collaborations highlight the importance of research in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…